AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Pieris Pharmaceuticals Inc (NASDAQ:PIRS)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 13.6 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 80.800/9.660 |
| EBITDA (in USD) | -13.94M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -11.40 |
| Total Assets (in USD) | 38.68M |
|---|---|
| Total Liabilities (in USD) | 11.922M |
| Revenue TTM (in USD) | 42.81M |
| Cash (in USD) | 17.396M |
| Market Cap (in USD) | 13.836 M |
| Revenue Per Share TTM | 38.026 |
| Gross Profit TTM (in USD) | -27.08M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Employees: 46
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Frank Vollmering | VP of HR | NA |
| 2. | Mr. Stephen S. Yoder J.D. | CEO, Pres & Director | 1976 |
| 3. | Dr. Hitto Kaufmann Ph.D. | Sr. VP & Chief Scientific Officer | 1971 |
| 4. | Mr. Thomas Bures | Sr. VP & CFO | 1974 |
| 5. | Maria Kelman | Exec. Director of Investor Relations | NA |
| 6. | Mr. Ahmed S. Mousa J.D. | Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec. | 1985 |
| 7. | Dr. Christine Rothe Ph.D. | VP and Head of Early Stage Project Leadership & Data Science | NA |
| 8. | Dr. Shane Olwill Ph.D. | Sr. VP & Chief Devel. Officer | 1976 |
| 9. | Mr. Prompong Chaikul | Chief Supply Chain Officer | 1987 |
| 10. | Dr. Gordon Otto M.D., Ph.D. | Head of Clinical Devel. Oncology | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.750 4.167% | 43.09 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.780 4.216% | 43.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+13.400 3.128% | 434.95 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+9.780 1.580% | 628.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -33.277M | -45.738M | -37.066M | -25.469M | -27.066M |
| Minority Interest | - | - | - | - | - |
| Net Income | -31.253M | -43.366M | -37.23M | -23.755M | -26.754M |
| Selling General Administrative | 16.394M | 16.593M | 16.713M | 18.44M | 18.442M |
| Gross Profit | 25.902M | 31.418M | 29.323M | 46.279M | 29.101M |
| Reconciled Depreciation | 2.78M | 2.368M | 2.127M | 1.04M | 0.57M |
| Ebit | -43.474M | -51.831M | -33.921M | -27.157M | -30.831M |
| Ebitda | -35.301M | -48.146M | -31.794M | -26.117M | -30.261M |
| Depreciation And Amortization | 8.173M | 3.685M | 2.127M | 1.04M | 0.57M |
| Operating Income | -43.474M | -51.831M | -33.921M | -27.157M | -30.831M |
| Other Operating Expenses | 61.203M | 79.564M | 63.244M | 73.436M | 59.932M |
| Interest Expense | -10.197M | 6.093M | 3.145M | 1.688M | 3.765M |
| Tax Provision | - | 0M | 0.164M | 0M | -0.312M |
| Interest Income | 0.721M | 0.004M | 0.511M | 1.714M | 1.962M |
| Net Interest Income | 0.721M | 0.004M | 0.511M | 1.714M | 1.962M |
| Income Tax Expense | -2.024M | -2.372M | 0.164M | -1.714M | -0.312M |
| Total Revenue | 25.902M | 31.418M | 29.323M | 46.279M | 29.101M |
| Total Operating Expenses | 61.203M | 79.564M | 63.244M | 73.436M | 59.932M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | 10.197M | 6.093M | -3.145M | 1.688M | 3.765M |
| Net Income From Continuing Ops | -33.277M | -45.738M | -37.23M | -25.469M | -26.754M |
| Net Income Applicable To Common Shares | - | -45.738M | -37.23M | -28.299M | -26.754M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 38.68M | 95.49M | 153.56M | 105.01M | 141.097M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 6.275M | 8.445M | 6.548M | 3.579M | 4.072M |
| Total Liab | 11.922M | 67.561M | 102.805M | 73.983M | 89.745M |
| Total Stockholder Equity | 26.758M | 27.929M | 50.755M | 31.027M | 51.352M |
| Other Current Liab | 8.55M | 10.746M | 15.787M | 5.481M | 4.96M |
| Common Stock | 0.098M | 0.074M | 0.072M | 0.056M | 0.055M |
| Capital Stock | - | 0.074M | 0.072M | 0.056M | 0.055M |
| Retained Earnings | -314.964M | -290.421M | -257.144M | -211.406M | -174.176M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 2.904M | 7.243M | 3.146M |
| Cash | 17.396M | 38.635M | 117.764M | 70.436M | 62.26M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 11.922M | 36.583M | 50.561M | 22.145M | 27.003M |
| Current Deferred Revenue | - | 20.824M | 25.116M | 12.627M | 11.256M |
| Net Debt | -17.396M | -25.532M | -103.923M | -53.474M | -46.043M |
| Short Term Debt | - | 0.859M | 1.049M | 1.03M | 0.733M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | - | 13.103M | 13.841M | 16.962M | 16.217M |
| Other Stockholder Equity | 341.596M | 318.53M | 306.998M | 242.672M | 227.468M |
| Property Plant Equipment | - | 20.697M | 23.031M | 25.98M | 19.502M |
| Total Current Assets | 38.68M | 73.424M | 127.625M | 75.721M | 115.013M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 8.97M | 20.534M | 0M | 0M | 41.894M |
| Net Receivables | 6.039M | 5.81M | 3.313M | 1.706M | 6.787M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 3.372M | 4.154M | 8.609M | 3.007M | 10.054M |
| Accumulated Other Comprehensive Income | 0.028M | -0.254M | 0.829M | -0.295M | -1.995M |
| Non Currrent Assets Other | - | 1.369M | 2.904M | 3.309M | 3.146M |
| Non Current Assets Total | - | 22.066M | 25.935M | 29.289M | 26.084M |
| Capital Lease Obligations | - | 13.103M | 14.89M | 16.962M | 16.217M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -21.236M | -0.949M | 41.938M | 12.3M | -7.177M |
| Total Cashflows From Investing Activities | - | -0.949M | 39.212M | 9.838M | -8.875M |
| Total Cash From Financing Activities | 7.214M | 59.127M | 10.115M | 32.166M | 48.511M |
| Net Income | -33.277M | -45.738M | -37.23M | -25.469M | -26.754M |
| Change In Cash | -79.129M | 47.328M | 8.176M | -12.607M | 36.989M |
| Begin Period Cash Flow | 117.764M | 70.436M | 62.26M | 74.867M | 37.878M |
| End Period Cash Flow | 38.635M | 117.764M | 70.436M | 62.26M | 74.867M |
| Total Cash From Operating Activities | -59.932M | -7.66M | -45.896M | -52.467M | -1.066M |
| Depreciation | 2.78M | 2.368M | 2.127M | 1.04M | 0.57M |
| Other Cashflows From Investing Activities | - | - | - | 12.3M | -7.177M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 5.734M | -2.87M | -0.799M | - |
| Sale Purchase Of Stock | - | 59.127M | 10.115M | 32.213M | 48.511M |
| Other Cashflows From Financing Activities | 0.292M | 2.026M | 0.491M | 1.168M | 1.3M |
| Capital Expenditures | 1.041M | 0.949M | 2.726M | 2.462M | 1.698M |
| Change In Working Capital | -33.37M | 30.525M | -16.377M | -32.121M | 21.893M |
| Other Non Cash Items | -0.467M | -0.03M | 0.33M | -0.069M | -1.554M |
| Free Cash Flow | -60.973M | -8.609M | -48.622M | -54.929M | -2.764M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 885502 |
| 2. | Fidelity Extended Market Index | 2 years ago | 512413 |
| 3. | NT Ext Equity Mkt Idx Fd - NL | 2 years ago | 165662 |
| 4. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 years ago | 133050 |
| 5. | BlackRock Extended Mkt Composite | 2 years ago | 129282 |
| 6. | BlackRock Extended Equity Market K | 2 years ago | 112828 |
| 7. | Fidelity Total Market Index | 2 years ago | 100668 |
| 8. | Fidelity Series Total Market Index | 2 years ago | 86908 |
| 9. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 70643 |
| 10. | Northern Trust Extended Eq Market Idx | 2 years ago | 70643 |
| 11. | SSgA U.S. Extended Market Index Class I | 2 years ago | 31300 |
| 12. | State St US Extended Mkt Indx NL Cl C | 2 years ago | 31300 |
| 13. | Spartan Total Market Index Pool E | 2 years ago | 28491 |
| 14. | Fidelity Nasdaq Composite Index | 2 years ago | 22483 |
| 15. | Vanguard U.S. Eq Idx £ Acc | 2 years ago | 21888 |
| 16. | Spartan Extended Market Index Pool E | 2 years ago | 21102 |
| 17. | BlackRock U.S. Equity Market F | 2 years ago | 15464 |
| 18. | Extended Equity Market Fund M | 2 years ago | 13918 |
| 19. | SSgA U.S. Total Market Index Strategy | 2 years ago | 9028 |
| 20. | Northern Trust Wilshire 5000 | 2 years ago | 7037 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Renaissance Technologies Corp | 2 years ago | 1065007 |
| 2. | BlackRock Inc | 2 years ago | 1037747 |
| 3. | Acadian Asset Management LLC | 2 years ago | 962358 |
| 4. | Vanguard Group Inc | 2 years ago | 907390 |
| 5. | Geode Capital Management, LLC | 2 years ago | 761444 |
| 6. | CM Management, LLC | 2 years ago | 750000 |
| 7. | Northern Trust Corp | 2 years ago | 243592 |
| 8. | State Street Corporation | 2 years ago | 222819 |
| 9. | Millennium Management LLC | 2 years ago | 166685 |
| 10. | Summit Trail Advisors, LLC | 2 years ago | 140000 |
| 11. | Prudential Financial Inc | 2 years ago | 110200 |
| 12. | Susquehanna International Group, LLP | 2 years ago | 102971 |
| 13. | Virtu Financial LLC | 2 years ago | 90059 |
| 14. | Citigroup Inc | 2 years ago | 88585 |
| 15. | Goldman Sachs Group Inc | 2 years ago | 45266 |
| 16. | Two Sigma Investments LLC | 2 years ago | 40914 |
| 17. | Bank of New York Mellon Corp | 2 years ago | 39949 |
| 18. | XTX Topco Ltd | 2 years ago | 39689 |
| 19. | Two Sigma Advisers, LLC | 2 years ago | 34600 |
| 20. | NJ State Employees Deferred Compnstin Pl | 2 years ago | 30000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...